MX340670B - Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog. - Google Patents

Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.

Info

Publication number
MX340670B
MX340670B MX2012002460A MX2012002460A MX340670B MX 340670 B MX340670 B MX 340670B MX 2012002460 A MX2012002460 A MX 2012002460A MX 2012002460 A MX2012002460 A MX 2012002460A MX 340670 B MX340670 B MX 340670B
Authority
MX
Mexico
Prior art keywords
taxane
combination therapy
nanoparticle compositions
hedgehog inhibitors
hedgehog
Prior art date
Application number
MX2012002460A
Other languages
English (en)
Other versions
MX2012002460A (es
Inventor
Patrick Soon-Shiong
Neil P Desai
Chunlin Tao
Original Assignee
Abraxis Bioscience Llc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc * filed Critical Abraxis Bioscience Llc *
Publication of MX2012002460A publication Critical patent/MX2012002460A/es
Publication of MX340670B publication Critical patent/MX340670B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee métodos de terapia combinada para el tratamiento de una enfermedad proliferativa (tal como cáncer) que comprenden administrar a un individuo una cantidad efectiva de un taxano en una composición de nanopartículas y un inhibidor de hedgehog que inhibe una ruta de señalización de hedgehog.
MX2012002460A 2009-08-25 2010-08-25 Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog. MX340670B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23681309P 2009-08-25 2009-08-25
PCT/US2010/046684 WO2011025838A1 (en) 2009-08-25 2010-08-25 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors

Publications (2)

Publication Number Publication Date
MX2012002460A MX2012002460A (es) 2012-05-08
MX340670B true MX340670B (es) 2016-07-20

Family

ID=43628371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002460A MX340670B (es) 2009-08-25 2010-08-25 Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.

Country Status (26)

Country Link
US (2) US20130045240A1 (es)
EP (2) EP2470173B1 (es)
JP (1) JP2013503174A (es)
KR (1) KR20120053052A (es)
CN (1) CN102573832B (es)
AU (1) AU2010286670B2 (es)
BR (1) BR112012004149A2 (es)
CA (1) CA2772301A1 (es)
CR (1) CR20120115A (es)
DK (1) DK2470173T3 (es)
ES (1) ES2577024T3 (es)
HR (1) HRP20160551T8 (es)
HU (1) HUE029094T2 (es)
IL (1) IL218316A (es)
IN (1) IN2012DN02018A (es)
MX (1) MX340670B (es)
MY (1) MY162514A (es)
NI (1) NI201200030A (es)
NZ (1) NZ598588A (es)
PL (1) PL2470173T3 (es)
PT (1) PT2470173E (es)
RU (1) RU2561055C2 (es)
SG (2) SG10201609290PA (es)
UA (1) UA110196C2 (es)
WO (1) WO2011025838A1 (es)
ZA (1) ZA201201531B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2880727C (en) * 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20150002886A (ko) * 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
SG186109A1 (en) * 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
JP6257324B2 (ja) * 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
EP3056201A1 (en) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
US8779149B2 (en) * 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
SMT201900502T1 (it) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014087413A1 (en) * 2012-12-03 2014-06-12 Vishwa Vidya Peetham University Amrita Nanoparticles comprising sorafenib
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) * 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014179678A1 (en) * 2013-05-03 2014-11-06 Angiostrass Llc Methods of treating cancer and angioproliferative disorders
RU2681849C2 (ru) * 2013-06-05 2019-03-13 Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ Гетероциклические производные и их применение
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
AR097685A1 (es) * 2013-09-17 2016-04-06 Genentech Inc Métodos de uso de anticuerpos anti-lgr5
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
CN106421786A (zh) * 2015-08-06 2017-02-22 复旦大学 Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
JP2022543021A (ja) * 2019-05-29 2022-10-07 ネルム コーポレーション がんを処置する方法及び使用
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN112755042A (zh) * 2019-11-06 2021-05-07 绍兴维帆生物技术有限公司 一种抗肿瘤药物的联合使用治疗白血病的方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
WO2025120550A1 (ko) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법
WO2025120551A1 (ko) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법
CN120177781B (zh) * 2025-05-22 2025-08-12 南京师范大学 生物传感器及其应用和高通量筛选花姜酮生产菌的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR100904931B1 (ko) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
EP1133519B1 (en) 1998-11-02 2008-08-13 Curis, Inc. Functional antagonists of hedgehog activity
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU767066B2 (en) 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
AU782493B2 (en) 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20050192262A1 (en) * 2001-03-13 2005-09-01 Tomas Hagstrom Treatment of tumours
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US20070281040A1 (en) * 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2008121102A2 (en) 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
DE102006038747A1 (de) 2006-08-17 2008-03-20 Khs Ag Dichtanordnung für eine Drehlagervorrichtung
JP4897518B2 (ja) 2007-03-02 2012-03-14 株式会社ニチベイ ブラインドの操作装置
JP5577104B2 (ja) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
JP5550352B2 (ja) * 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
JP5373777B2 (ja) * 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体
US20090123932A1 (en) * 2007-11-09 2009-05-14 Anne-Marie Mes-Masson Quantitative test to detect disease progression markers of epithelial ovarian cancer patients
CN101918420A (zh) * 2007-12-27 2010-12-15 无限药品股份有限公司 癌症治疗方法
EP2235063B1 (en) * 2007-12-28 2015-09-02 Genentech, Inc. Anti-hedgehog antibodies

Also Published As

Publication number Publication date
MY162514A (en) 2017-06-15
PT2470173E (pt) 2016-06-15
SG10201609290PA (en) 2016-12-29
EP2470173A1 (en) 2012-07-04
EP2470173B1 (en) 2016-04-27
NZ598588A (en) 2014-05-30
CN102573832B (zh) 2015-07-22
RU2012111235A (ru) 2013-10-10
EP2470173A4 (en) 2013-06-19
HRP20160551T1 (hr) 2016-09-23
HK1172550A1 (zh) 2013-04-26
ZA201201531B (en) 2013-05-29
CN102573832A (zh) 2012-07-11
MX2012002460A (es) 2012-05-08
ES2577024T3 (es) 2016-07-12
CR20120115A (es) 2012-09-04
UA110196C2 (uk) 2015-12-10
IL218316A0 (en) 2012-04-30
WO2011025838A1 (en) 2011-03-03
IN2012DN02018A (es) 2015-07-31
HUE029094T2 (hu) 2017-02-28
RU2561055C2 (ru) 2015-08-20
SG178873A1 (en) 2012-04-27
PL2470173T3 (pl) 2016-11-30
CA2772301A1 (en) 2011-03-03
DK2470173T3 (en) 2016-06-06
US20130045240A1 (en) 2013-02-21
AU2010286670A1 (en) 2012-03-29
US20140072630A1 (en) 2014-03-13
IL218316A (en) 2016-04-21
KR20120053052A (ko) 2012-05-24
JP2013503174A (ja) 2013-01-31
EP3103452A1 (en) 2016-12-14
NI201200030A (es) 2012-12-06
HRP20160551T8 (hr) 2016-11-18
BR112012004149A2 (pt) 2016-03-22
AU2010286670B2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
MY162514A (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MY162903A (en) Methods of treatment of pancreatic cancer
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
NZ700759A (en) Combination therapy for treating cancer
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
CR20120202A (es) Métodos y composiciones para tratar cáncer
CO6321188A2 (es) Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
GB201114051D0 (en) Compounds and their uses
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2012135528A3 (en) Galectin-3c combination therapy for human cancer
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2014006662A (es) Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
GB201312583D0 (en) Combination and composition for treating obesity
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.

Legal Events

Date Code Title Description
FG Grant or registration